Finance

Lists
532488:BOM
Divi's Laboratories Ltd
9 220,00 INR
+1,99%
(+180,05) 1D
16 ოქტ, 15:56:15 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 532488...
Open
9 013,35 INR
High
9 247,50 INR
Low
8 985,00 INR
Mkt. cap
2,45 ტრლ.
Avg. vol.
33,69 ათ.
Volume
17,22 ათ.
Dividend
0,33%
Quarterly dividend
7,50 INR
Ex-dividend date
24 ივლ. 2026
P/E ratio
83,67
52-wk high
10 000,00 INR
52-wk low
5 648,00 INR
EPS
110,20 INR
Shares outstanding
265,47 მლნ.
No. of employees
12 ათ.
Open
9 013,35 INR
High
9 247,50 INR
Low
8 985,00 INR
Mkt. cap
2,45 ტრლ.
Avg. vol.
33,69 ათ.
Volume
17,22 ათ.
Dividend
0,33%
Quarterly dividend
7,50 INR
Ex-dividend date
24 ივლ. 2026
P/E ratio
83,67
52-wk high
10 000,00 INR
52-wk low
5 648,00 INR
EPS
110,20 INR
Shares outstanding
265,47 მლნ.
No. of employees
12 ათ.
News stories
From web sources and news partners
Profile
Divi's Laboratories Limited is an Indian multinational pharmaceutical company and producer of active pharmaceutical ingredients and intermediates, headquartered in Hyderabad. The company manufactures and custom synthesizes generic APIs, intermediates. The company also manufactures and supplies nutraceutical ingredients through its subsidiary, Divi's Nutraceuticals. Divi's Laboratories is India's fourth largest publicly listed pharmaceutical company by market capitalization. Wikipedia
About Divi's Laboratories Ltd
CEOკირან ეს დივი
Employees11,6 ათ.
Founded12 ოქტ. 1990
Headquarters-
SectorHealth care
Websitedivislabs.com
Last report
1 აგვ. 2026
Fiscal period
Q1 2027
33,95 INR / 24,68 INR
+37,58%beat
Revenue / Est. (INR)
30,80 მლრდ. / 27,61 მლრდ.
+11,56%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
27,15 მლრდ.
26,04 მლრდ.
28,31 მლრდ.
30,80 მლრდ.
Cost of goods sold
10,73 მლრდ.
9,45 მლრდ.
13,49 მლრდ.
9,86 მლრდ.
Cost of revenue
10,73 მლრდ.
9,45 მლრდ.
13,49 მლრდ.
9,86 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,54 მლრდ.
3,67 მლრდ.
3,99 მლრდ.
4,08 მლრდ.
Operating expense
8,67 მლრდ.
8,87 მლრდ.
6,68 მლრდ.
9,65 მლრდ.
Total operating expenses
19,40 მლრდ.
18,32 მლრდ.
20,17 მლრდ.
19,51 მლრდ.
Operating income
7,75 მლრდ.
7,72 მლრდ.
8,14 მლრდ.
11,29 მლრდ.
Other non operating income
820,00 მლნ.
690,00 მლნ.
-2,23 მლრდ.
640,00 მლნ.
EBT including unusual items
9,12 მლრდ.
7,80 მლრდ.
9,63 მლრდ.
11,80 მლრდ.
EBT excluding unusual items
9,12 მლრდ.
8,54 მლრდ.
9,59 მლრდ.
11,80 მლრდ.
Income tax expense
2,23 მლრდ.
1,97 მლრდ.
2,12 მლრდ.
2,78 მლრდ.
Effective tax rate
24,45%
25,26%
22,01%
23,56%
Other operating expenses
4,00 მლრდ.
4,02 მლრდ.
1,49 მლრდ.
4,24 მლრდ.
Net income
6,89 მლრდ.
5,83 მლრდ.
7,51 მლრდ.
9,02 მლრდ.
Net profit margin
25,38%
22,39%
26,53%
29,29%
Earnings per share
25,97
24,07
28,31
33,95
Interest and investment income
-
-
2,84 მლრდ.
-
Interest expense
-80,00 მლნ.
-60,00 მლნ.
-60,00 მლნ.
-60,00 მლნ.
Net interest expenses
-80,00 მლნ.
-60,00 მლნ.
2,78 მლრდ.
-60,00 მლნ.
Depreciation and amortization charges
1,13 მლრდ.
1,18 მლრდ.
1,20 მლრდ.
1,33 მლრდ.
EBITDA
8,88 მლრდ.
8,72 მლრდ.
9,29 მლრდ.
12,44 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები